His primary areas of investigation include Cell biology, Apoptosis, Autophagy, Programmed cell death and Mitochondrion. His studies in Cell biology integrate themes in fields like Ubiquitin, Biochemistry, Transgene and Bcl-2-associated X protein. His research in the fields of Cytochrome c, Fas receptor and Truncated BID overlaps with other disciplines such as Cathepsin B.
His research integrates issues of Liver injury, Pharmacology and Fatty liver in his study of Autophagy. Xiao Ming Yin focuses mostly in the field of Programmed cell death, narrowing it down to matters related to Signal transduction and, in some cases, Bcl-2 family, Cell loss and Ischemia. His work on Inner mitochondrial membrane as part of general Mitochondrion research is frequently linked to Calpastatin, thereby connecting diverse disciplines of science.
His main research concerns Cell biology, Autophagy, Apoptosis, Mitochondrion and Cancer research. Xiao Ming Yin has researched Cell biology in several fields, including Biochemistry and Programmed cell death. The concepts of his Programmed cell death study are interwoven with issues in Cancer cell, Cell and Proteasome inhibitor, Proteasome.
His study of Autophagosome is a part of Autophagy. His Mitochondrion research is multidisciplinary, incorporating elements of Molecular biology, Reactive oxygen species, Mitophagy and Mitochondrial permeability transition pore. The Cancer research study which covers Carcinogenesis that intersects with Liver tumor.
Xiao Ming Yin spends much of his time researching Autophagy, Cancer research, Cell biology, HMGB1 and Fatty liver. The Autophagy study combines topics in areas such as Carcinogenesis, Liver injury and Homeostasis. His Cancer research research includes elements of Cancer, Pathogenesis, Inflammation, Fibrosis and Acute kidney injury.
His Cell biology research incorporates elements of Programmed cell death and PINK1, Mitophagy. His Programmed cell death research is multidisciplinary, relying on both Autolysosome, Multicellular organism and In vivo. He combines topics linked to Apoptosis with his work on Mitochondrion.
The scientist’s investigation covers issues in Autophagy, Cell biology, Cancer research, Programmed cell death and Mitochondrion. His Autophagy research incorporates themes from Cytoplasm, Steatosis, Homeostasis, Liver injury and Fatty liver. His Cell biology research includes themes of Cell, Hepatic stellate cell and Cell cycle checkpoint.
His studies in Cancer research integrate themes in fields like Cancer, Cancer therapy, Gene, Fibrosis and Acute kidney injury. His research in Programmed cell death intersects with topics in ATG8, In vitro, Cytotoxicity, Cancer cell and In vivo. His Mitochondrion study combines topics from a wide range of disciplines, such as Apoptosis, Reactive oxygen species and Organelle.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
Daniel J. Klionsky;Amal Kamal Abdel-Aziz;Sara Abdelfatah;Mahmoud Abdellatif.
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin.
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
David M. Hockenbery;David M. Hockenbery;Zoltan N. Oltvai;Xiao Ming Yin;Curt L. Milliman.
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Daniel J. Klionsky;Hagai Abeliovich;Patrizia Agostinis;Devendra K. Agrawal.
BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax
Xiao Ming Yin;Zoltan N Oltvai;Stanley J. Korsmeyer.
Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death.
Atan Gross;Xiao Ming Yin;Kun Wang;Michael C. Wei.
Journal of Biological Chemistry (1999)
Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis
Xiao-Ming Yin;Kun Wang;Atan Gross;Atan Gross;Yongge Zhao.
BID: a novel BH3 domain-only death agonist.
Kun Wang;Xiao Ming Yin;Debra T. Chao;Curt L. Milliman.
Genes & Development (1996)
Principles and current strategies for targeting autophagy for cancer treatment.
Ravi K. Amaravadi;Jennifer Lippincott-Schwartz;Xiao Ming Yin;William A. Weiss.
Clinical Cancer Research (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: